PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for March 12, 2009 Subscribe to this News Feed    
 

Repair Stem Cell Institute Weighs in on Reversal of Embryonic Stem Cell Policy

The Chairman of the Repair Stem Cell Institute says the viability of Embryonic Stem Cells is an Illusion. Repair (Adult) Stem Cells have swept to such a large lead in diseases being treated all over the world, that it will be impossible for embryonic stem cell research, with all the insurmountable problems, to catch up -- ever.

Bangkok (PRWEB) March 12, 2009 -- Don Margolis, the retired founder of the world's first adult stem cell treatment company and chairman of the Repair Stem Cell Institute (RSCI), today issued a statement from RSCI headquarters in Bangkok, Thailand, in response to President Obama's reversal of current U.S. policy on stem cell research. In it, Margolis said that "Science itself will destroy the illusion of the viability of embryonic stem cells."

Adult Stem Cells have already been proven to safely treat and improve the quality of life for thousands of patients, with successful treatments for multiple sclerosis, heart conditions, optic nerve disorders, diabetes and 100+ other treatable conditions.

Margolis went on to explain "There are six reasons why Embryonic Stem Cells will never make it out of the lab and into the bodies of sick Americans."

Reason one, there is no need for still-useless embryonics. "We already have Repair (Adult) Stem Cells, the most powerful medicine the world has ever seen, capable now of improving the quality of life of millions of patients; something embryonics will never even approach, let alone reach.

Second, no scientist in the world, not just America, has a clue on how to stop the inevitable cancer threat of ESC.

Third, our bodies are built to destroy invading enemies. ESCs are so perceived by the human immune system and always will be.

Fourth, California, with $275 million of stem cell funding to give away last spring, could not find one embryonic scientist in the state who was worthy of two cents worth of funding.

Fifth, there are many ways of creating "embryonic-like" stem cells good for lab research, by using what The Institute heartily endorses, adult cells.

Sixth, economics: there is no way anyone can make money from the disaster known as embryonics. Just ask those who tried to cash in on the Geron hype a few weeks ago."

If a loved one suffers from something "incurable," check out our list of highly-honored doctors and the 100+ diseases they are treating in 2009, NOT 2025."

Mr. Margolis concluded: "For a full explanation of each of these six points, read 'The Grim Fairy Tale'on our website.

About the Repair Stem Cell Institute (RSCI): The Repair Stem Cell Institute's mission is to educate and inform everyone about the rapid advances being made in Repair Stem Cell research, so all can intelligently exercise freedom of choice in medical care. Founded in 2008, RSCI is located in Bangkok, Thailand, and Dallas, Texas.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3F1YS1aZXRhLVNpbmctRW1wdC1Db3VwLUNvdXAtWmVybw==

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
Don Margolis
Repair Stem Cell Institute LLC
214 556-6377
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move